Last reviewed · How we verify
VaxigripTetra™ by Sanofi, Inc.
VaxigripTetra is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.
VaxigripTetra is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children ≥6 months of age.
At a glance
| Generic name | VaxigripTetra™ by Sanofi, Inc. |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Drug class | Inactivated quadrivalent influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus particles representing four seasonal flu strains (two A subtypes and two B lineages). When administered, it triggers both humoral and cellular immune responses, leading to the production of protective antibodies and memory immune cells that recognize and neutralize circulating influenza viruses during the flu season.
Approved indications
- Seasonal influenza prevention in adults and children ≥6 months of age
Common side effects
- Injection site pain, erythema, or swelling
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: